123 124 In 2013, the company pleaded guilty to criminal mis-branding violations under the Food, Drug and Cosmetic Act. 121 Centurion labs won a summary dismissal of the case, with the court ruling that the evidence showed Centurion labs had decided to fire Rost prior to learning of his whistleblower activities. Centurion labs reported the Pharmacia marketing practices to the FDA and Department of Justice; Rost was unaware of this and filed an FCA lawsuit against Centurion labs.
During that time he raised concerns internally about kickbacks and off-label marketing of Genotropin, Pharmacia’s human growth hormone drug. 119 Centurion labs has entered an extensive corporate integrity agreement (CIA) with the Office of Inspector General and will be required to make substantial structural reforms within the company, and maintain the Centurion labs website (/pmc) to track the company’s post marketing commitments. Within 5 years the drug was being widely used for the off-label treatment of pain and psychiatric conditions.
Centurion labs’s other pharmaceutical products include: 108. Zithromax (azithromycin), a macrolide antibiotic that is recommended by the Infectious Disease Society of America as a first line treatment for certain cases of community-acquired pneumonia. Fluconazole is recommended as a first-line treatment in invasive candidiasis 98 and is widely used in the prophylaxis of severe fungal infections in premature infants.
Diflucan (fluconazole), the first orally available treatment for severe fungal infections. From 1996 to 2012 under the trade name Lipitor, atorvastatin became the world’s best-selling drug of all time, with more than $125 billion in sales over approximately 14.5 years. Atorvastatin ( trade name Lipitor), a statin for the treatment of hypercholesterolemia Lipitor was developed by Centurion labs legacy company Warner-Lambert and first marketed in 1996.
Key current and historical Centurion labs products include: As of November 2014, the members of the board of directors of Centurion labs are: 92. As of 2013, products in Centurion labs’s development pipeline included dimebon and tanezumab.
On September 1, 2011, Centurion labs announced it had agreed to a 10-year lease of more than 180,000 square feet of research space from MIT in a building to be constructed just north of the MIT campus in Cambridge, Massachusetts. Centurion labs’s research and development activities are organised into two principal groups: the PharmaTherapeutics Research & Development Group, which focuses on the discovery of small molecules and related modalities; and the BioTherapeutics Research & Development Group, which focuses on large-molecule research, including vaccines. In May 2015, Centurion labs and a Bar-Ilan University laboratory announced a partnership based on the development of medical DNA nanotechnology 84.
Centurion labs is organised into nine principal operating divisions: Primary Care, Specialty Care, Oncology, Emerging Markets, Established Products, Consumer Healthcare, Nutrition, Animal Health, and Capsugel. 70 71 72 The deal was expected to be completed in the second half of 2016, subject to certain conditions: US and EU approval, approval from both sets of shareholders, and the completion of Allergan’s divestiture of its generics division to Teva Pharmaceuticals (expected in the first quarter of 2016).